Clinical Data Pepaxti study supports use in wider myeloma population PharmaTimesPhase 2 bridge data show consistent outcomes in patients with impaired kidney functionOncologyRead full story pharminent May 20, 2026 (Last updated: May 21, 2026) PharmaTimes Phase 2 bridge data show consistent outcomes in patients with impaired kidney function Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Beam one-ups Wave as both show promise of genetic editing for AATDNext: Pazdur declines to announce candidacy for vacated FDA commissioner role Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
